Skip to main content
SpringerLink
Log in

Tumor Biomarkers and Diagnosis of Pancreatic Adenocarcinoma

  • Chapter
  • First Online:
Novel therapeutic approaches for gastrointestinal malignancies

Part of the book series: Diagnostics and Therapeutic Advances in GI Malignancies ((DTAGIM))

  • 174 Accesses

Abstract

Pancreatic adenocarcinoma is one of the highly malignant cancers of gastrointestinal tract. Patients during the initial stages usually do not present characteristic signs and symptoms. Even if malignancy is suspected, differentiation between the malignant and benign conditions might be challenging. Recently, an increasing interest has been focused on the utility of immunological tumor markers. The use of tumor biomarkers aims at catching/identifying the cancer at a relatively earlier stage, surveillance, response to the treatment, endpoints, and any adverse effects. Based on biochemical characteristics, tumor markers can be classified into multiple groups including genetic, glycoproteins, ribonucleic acids (RNAs), proteins, oncofetal antigenic markers, metabolite-based markers, and so on. In this chapter, we sought to discuss some important biomarkers that can be useful in the diagnostic evaluation of pancreatic adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AUC:

Area under the curve

CA:

Carbohydrate antigen

CSF:

Cerebrospinal fluid

CTC:

Circulating tumor cells

ctDNA:

Circulating tumor deoxyribonucleic acid

EUS:

Endoscopic ultrasound

FDA:

Food and Drug Administration

FNA:

Fine needle aspiration

IGF:

Insulin-like growth factor

MIC-1:

Macrophage inhibitory cytokine-1

PAC:

Pancreatic adenocarcinoma

RNA:

Ribonucleic acid

TGF-β:

Transforming growth factor-β

References

  1. Selleck MJ, Senthil M, Wall NR (2017) Making meaningful clinical use of biomarkers. Biomark Insights 12:1177271917715236

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Holdenrieder S et al (2016) Clinically meaningful use of blood tumor markers in oncology. Biomed Res Int 2016:9795269. https://doi.org/10.1155/2016/9795269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Capello M et al (2017) Sequential validation of blood-based protein biomarker candidates for early-stage pancreatic cancer. J Natl Cancer Inst 109(4):184–194

    Article  CAS  Google Scholar 

  4. Chang JC, Kundranda M (2017) Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma. Int J Mol Sci 18(3):667

    Article  PubMed Central  CAS  Google Scholar 

  5. Su SB, Qin SY, Chen W, Luo W, Jiang HX (2015) Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol: WJG 21(14):4323–4333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ (2006) Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis 7(3):170–174

    Article  PubMed  Google Scholar 

  7. Jiang XT, Tao HQ, Zou SC (2004) Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 3(3):464–468

    CAS  PubMed  Google Scholar 

  8. Ćwik G, Wallner G, Skoczylas T, Ciechański A, Zinkiewicz K (2006) Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 141(10):968–973

    Article  PubMed  Google Scholar 

  9. Zhang Y, Yang J, Li H, Wu Y, Zhang H, Chen W (2015) Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med 8(7):11683–11691

    PubMed  PubMed Central  Google Scholar 

  10. Chen YZ, Liu D, Zhao YX, Wang HT, Gao Y, Chen Y (2014) Diagnostic performance of serum macrophage inhibitory cytokine-1 in pancreatic cancer: a meta-analysis and meta-regression analysis. DNA Cell Biol 33(6):370–377

    Article  CAS  PubMed  Google Scholar 

  11. Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM (2013) PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer 119(3):522–528

    Article  CAS  PubMed  Google Scholar 

  12. Zihao G, Jie Z, Yan L, Jing Z, Jing C, Xue L, Jing Z, Heng LW, Ru G, Jianyu H (2013) Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens: a promising diagnostic method of pancreatic cancer. J Clin Gastroenterol 47(1):69–75

    Article  PubMed  Google Scholar 

  13. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ (2013) Serum osteopontin and TIMP-1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 42(2):193–197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ (2011) Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17(4):805–816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yang JY, Sun YW, Liu DJ, Zhang JF, Li J, Hua R (2014) MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Am J Cancer Res 4(6):663–673

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Wang J et al (2009) MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res 2:807–813. https://doi.org/10.1158/1940-6207.CAPR-09-0094

    Article  CAS  Google Scholar 

  17. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC (2010) Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 3(2):109–113

    Article  PubMed  PubMed Central  Google Scholar 

  18. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA (2007) MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30):4442–4452

    Article  CAS  PubMed  Google Scholar 

  19. Debernardi S, Massat NJ, Radon TP, Sangaralingam A, Banissi A, Ennis DP, Dowe T, Chelala C, Pereira SP, Kocher HM, Young BD (2015) Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. Am J Cancer Res 5(11):3455–3466

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H (2006) Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 97(11):1191–1197

    Article  CAS  PubMed  Google Scholar 

  21. Märten A, Büchler MW, Werft W, Wente MN, Kirschfink M, Schmidt J (2010) Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology. J Immunother 33(2):219–224

    Article  PubMed  CAS  Google Scholar 

  22. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S et al (2009) A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6(4):e1000046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Goh SK et al (2017) Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg 87(12):987–992

    Article  PubMed  Google Scholar 

  24. Kaur S et al (2012) Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med 6(5):597–612

    Article  CAS  PubMed  Google Scholar 

  25. Goonetilleke K, Siriwardena A (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33(3):266–270

    Article  CAS  PubMed  Google Scholar 

  26. O’Brien DP et al (2015) Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res 21(3):622–631

    Article  PubMed  Google Scholar 

  27. Ferri MJ et al (2016) Improved pancreatic adenocarcinoma diagnosis in jaundiced and non-jaundiced pancreatic adenocarcinoma patients through the combination of routine clinical markers associated to pancreatic adenocarcinoma pathophysiology. PLoS One 11(1):e0147214

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350

    Article  CAS  PubMed  Google Scholar 

  29. Haug U et al (2008) Stool testing for the early detection of pancreatic cancer: rationale and current evidence. Expert Rev Mol Diagn 8(6):753–759

    Article  CAS  PubMed  Google Scholar 

  30. Yonemori K et al (2017) MicroRNA in pancreatic cancer. J Hum Genet 62(1):33

    Article  CAS  PubMed  Google Scholar 

  31. Navon R et al (2009) Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 4(11):e8003

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Weber JA et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56(11):1733–1741

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhao H et al (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 5(10):e13735

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Liu J et al (2011) Diagnostic value of plasma miR 55 for pancreatic cancer. Chin J Pancreatol 11(2):79–81

    Google Scholar 

  35. Sun X et al (2018) Systematic review and meta-analysis of diagnostic accuracy of miRNAs in patients with pancreatic cancer. Dis Markers 2018:6292396. https://doi.org/10.1155/2018/6292396

    Article  PubMed  PubMed Central  Google Scholar 

  36. Ganepola GA et al (2014) Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol 6(1):22

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wan C et al (2012) Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. Arch Med Sci 8(5):749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ding Z et al (2014) MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles. Tumor Biol 35(9):8837–8848

    Article  CAS  Google Scholar 

  39. Pei Z, Liu SM, Huang JT, Zhang X, Yan D, Xia Q et al (2017) Clinically relevant circulating microRNA profiling studies in pancreatic cancer using meta-analysis. Oncotarget 8(14):22616

    Article  PubMed  PubMed Central  Google Scholar 

  40. Bootcov MR et al (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci USA 94(21):11514–11519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton GM, Brown DA et al (2009) Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Investig Dermatol 129(2):383–391

    Article  CAS  PubMed  Google Scholar 

  42. Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG, Kuffner T et al (2011) The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29(5):187–195

    Article  CAS  PubMed  Google Scholar 

  43. Buckhaults P, Rago C, Croix BS, Romans KE, Saha S, Zhang L et al (2001) Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 61(19):6996–7001

    CAS  PubMed  Google Scholar 

  44. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR et al (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci 100(6):3410–3415

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Misek DE et al (2007) Early detection and biomarkers in pancreatic cancer. J Natl Compr Cancer Netw 5(10):1034–1041

    Article  CAS  Google Scholar 

  46. Koopmann J et al (2006) Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12(2):442–446

    Article  CAS  PubMed  Google Scholar 

  47. Yang Y et al (2018) Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19–9 as a biomarker for diagnosis of pancreatic cancer: a PRISMA-compliant meta-analysis of diagnostic accuracy studies. Medicine 97(9):e9994. https://doi.org/10.1097/MD.0000000000009994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D (2016) Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30(6):836–848

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE et al (2012) Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 72:2473–2480

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B et al (2011) Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 68(16):2667–2688

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Suchorska WM, Lach MS (2016) The role of exosomes in tumor progression and metastasis. Oncol Rep 35(3):1237–1244

    Article  CAS  PubMed  Google Scholar 

  52. Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200(4):373–383

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Cocucci E, Meldolesi J (2015) Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol 25(6):364–372

    Article  CAS  PubMed  Google Scholar 

  54. Kailemia MJ, Park D, Lebrilla CB (2017) Glycans and glycoproteins as specific biomarkers for cancer. Anal Bioanal Chem 409(2):395–410

    Article  CAS  PubMed  Google Scholar 

  55. Munkley J, Elliott DJ (2016) Hallmarks of glycosylation in cancer. Oncotarget 7(23):35478

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hart GW (2016) Myriad roles of glycans in biology. J Mol Biol 16(428):3147–3149

    Article  CAS  Google Scholar 

  57. Kuzmanov U, Kosanam H, Diamandis EP (2013) The sweet and sour of serological glycoprotein tumor biomarker quantification. BMC Med 11(1):31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Silva MLS (2015) Cancer serum biomarkers based on aberrant post-translational modifications of glycoproteins: clinical value and discovery strategies. Biochim Biophys Acta 1856(2):165–177

    CAS  PubMed  Google Scholar 

  59. Peracaula R et al (2008) Altered glycosylation in tumours focused to cancer diagnosis. Dis Mark 25(4–5):207–218

    Article  CAS  Google Scholar 

  60. Meany DL, Chan DW (2011) Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics 8(1):7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Makawita S et al (2011) Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics 10(10):M111.008599. https://doi.org/10.1074/mcp.M111.008599

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Chen R et al (2006) Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 6(13):3871–3879

    Article  CAS  PubMed  Google Scholar 

  63. Pan S, Brentnall TA, Chen R (2016) Glycoproteins and glycoproteomics in pancreatic cancer. World J Gastroenterol 22:9288–9299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Zhou B et al (2017) Early detection of pancreatic cancer: where are we now and where are we going? Int J Cancer 141(2):231–241

    Article  CAS  PubMed  Google Scholar 

  65. Melo SA et al (2015) Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523:177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Hoshino A et al (2015) Tumour exosome integrins determine organotropic metastasis. Nature 527:329

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Bauden M et al (2017) Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma. BMC Cancer 17(1):810

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  68. Bettegowda C et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra24

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Kinugasa H et al (2015) Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer 121(13):2271–2280

    Article  CAS  PubMed  Google Scholar 

  70. Pishvaian MJ et al (2016) A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget 8(48):83446–83456

    Article  PubMed  PubMed Central  Google Scholar 

  71. Yi JM et al (2013) Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res 19(23):6544–6555

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Kulemann B et al (2017) Pancreatic cancer: circulating tumor cells and primary tumors show heterogeneous KRAS mutations. Sci Rep 7(1):4510

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Biankin AV et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Roberts NJ et al (2016) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6(2):166–175

    Article  CAS  PubMed  Google Scholar 

  75. Imamura T, Komatsu S, Ichikawa D, Kawaguchi T, Miyamae M, Okajima W et al (2016) Liquid biopsy in patients with pancreatic cancer: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 22(25):5627

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Riva F et al (2016) Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol 10(3):481–493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Liu J et al (2012) Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131(3):683–691

    Article  CAS  PubMed  Google Scholar 

  78. Cohen JD et al (2017) Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci USA 114(38):10202–10207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Sefrioui D et al (2017) Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer 117:1017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA et al (2017) A plasma biomarker panel to identify surgically resectable early-stage pancreatic cancer. J Natl Cancer Inst 109(8):djw341

    Article  PubMed Central  CAS  Google Scholar 

  81. Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C, Perdrix A, Paresy M, Antonietti M, Iwanicki-Caron I, Alhameedi R (2017) Diagnostic value of CA19. 9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer 117(7):1017–1025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Boulaiz H et al (2017) What’s new in the diagnosis of pancreatic cancer: a patent review (2011-present). Expert Opin Ther Pat 27(12):1319–1328

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Author contributions: Dr. Ishtiaq Hussain and Dr. Mamoon Ur Rashid conceived the idea and subsequently all the authors diligently contributed to the development and preparation of this research manuscript (book chapter), including the literature search, concept organization, data interpretation, and writings. All the authors have read and approved the final draft for publication.

Conflict of interest: The authors declare that they have no conflicts of interest associated with this research manuscript (book chapter).

Financial disclosures: None to disclose.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Cleveland Clinic, Weston, FL, USA

    Ishtiaq Hussain & Zarghoona Wajid

  2. Department of Internal Medicine, AdventHealth, Orlando, FL, USA

    Mamoon Ur Rashid & Deepika Sarvepalli

  3. Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI, USA

    Jamaluddin Saeed

  4. Services Institute of Medical Sciences, Lahore, Punjab, Pakistan

    Effa Zahid

  5. Khyber Teaching Hospital, Peshawar, Khyber Pakhtunkhwa, Pakistan

    Sundas Jehanzeb

  6. AdventHealth Cancer Institute, Orlando, FL, USA

    Sarfraz Ahmad

  7. FSU College of Medicine, Orlando, FL, USA

    Sarfraz Ahmad

  8. UCF College of Medicine, Orlando, FL, USA

    Sarfraz Ahmad

Authors
  1. Ishtiaq Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mamoon Ur Rashid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jamaluddin Saeed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zarghoona Wajid
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deepika Sarvepalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Effa Zahid
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sundas Jehanzeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sarfraz Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Mamoon Ur Rashid or Sarfraz Ahmad .

Editor information

Editors and Affiliations

  1. Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

    Ganji Purnachandra Nagaraju

  2. Department of Biotechnology, Dr. B.R. Ambedkar University, Srikakulam, Andhra Pradesh, India

    Sujatha Peela

Rights and permissions

Reprints and permissions

Copyright information

© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hussain, I. et al. (2020). Tumor Biomarkers and Diagnosis of Pancreatic Adenocarcinoma. In: Nagaraju, G.P., Peela, S. (eds) Novel therapeutic approaches for gastrointestinal malignancies. Diagnostics and Therapeutic Advances in GI Malignancies. Springer, Singapore. https://doi.org/10.1007/978-981-15-5471-1_14

Download citation

Publish with us

Policies and ethics

Search

Navigation